GlassScriptPhysician profile
Deborah Lopez Stegner
NPI 1033265715
$6,477.67
in general payments reported to CMS, 2019-2025
28 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $258 · 2021: $896 · 2022: $832 · 2023: $1,038 · 2024: $1,714 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.86 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.40 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $635.67 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $519.39 | 2021-2025 | Lybalvi |
| Lundbeck LLC | $507.07 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $469.15 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $467.71 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Vanda Pharmaceuticals INC. | $451.10 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $385.46 | 2022-2025 | Auvelity |
| Almatica Pharma LLC | $342.94 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.95 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $217.92 | 2021-2025 | Austedo Xr |
| Allergan, INC. | $160.49 | 2020 | |
| Neurocrine Biosciences, INC. | $128.13 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $85.75 | 2021 | |
| Ironshore Pharmaceuticals INC. | $71.44 | 2021-2023 | Jornay Pm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $65.87 | 2021-2024 | Aplenzin |
| Biogen, INC. | $58.21 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $51.81 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $38.77 | 2022-2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $38.07 | 2024-2025 | Relexxii |
| Tris Pharma INC | $31.10 | 2019-2022 | |
| Noven Therapeutics, LLC | $31.04 | 2024 | Xelstrym |
| Jazz Pharmaceuticals INC. | $29.91 | 2019 | |
| Eisai INC. | $27.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.81 | 2023 | Spravato |
| Corium, LLC | $21.00 | 2023 | Azstarys |
| Livanova USA, INC. | $20.16 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Harmony Biosciences LLC | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Stegner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.